On Jun. 3, 2018, findings were reported from the groundbreaking Trial Assigning Individualized Options for Treatment (Rx), or TAILOR trial, that showed no benefit from chemotherapy for 70 percent of women with the most common type of breast cancer.

The National Cancer Institute (NCI) funded study found that for women with hormone receptor (HR)-positive, HER2-negative, axillary lymph node-negative breast cancer, treatment with chemotherapy and hormone therapy after surgery was not more beneficial than treatment with hormone therapy alone.